You see, UCB wants to be a world leader when it comes to treating ailments related to the immune and central nervous systems (CNS).
UCB Pharma operates as a biopharmaceutical company with a focus on neurology and immunology diseases. The company leverages scientific advances and skills in areas such as genetics, biomarkers, and human biology.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 24, 2022 | Post-IPO Equity | €94.50M | 1 | Financière de Tubize SA | — | Detail |
May 13, 2015 | Post-IPO Equity | $787.62K | — | — | — | Detail |
Dec 22, 2009 | Post-IPO Equity | $100M | 1 | Paul Capital | — | Detail |
Jan 7, 2000 | IPO | — | — | — | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Oct 4, 2022
Bingli
|
Series A | €5.40M | Apps | — |
Jan 13, 2021
Nile AI
|
Corporate Round | €25M | Artificial Intelligence | Yes |
Feb 5, 2019
Aetion
|
Series B | $27M | Analytics | — |
Sep 25, 2018
Ceribell
|
Series B | $35M | Biotechnology | — |
Jun 13, 2018
StrideBio
|
Series A | $15.70M | Biotechnology | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Financière de Tubize SA | Yes | Post-IPO Equity |
Paul Capital | Yes | Post-IPO Equity |
UCB has had 3 exits. UCB most notable exits include Clementia Pharmaceuticals , Dermira
Date | Company Name | Exit Type | Industry | |
---|---|---|---|---|
Aug 22, 2017 | Clementia Pharmaceuticals | M&A | Biopharma | Detail |
Oct 3, 2014 | Dermira | M&A | Biopharma | Detail |
Jan 11, 2011 | Synosia Therapeutics | M&A | Biotechnology | Detail |
UCB has acquired 10 organizations. Their most recent acquisition was Celltech Therapeutics on May 18, 2004. They acquired Celltech Therapeutics for 0.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
May 18, 2004
Celltech Therapeutics
|
Biotechnology | acquisition | — | Detail |
Jan 1, 2006
Intranasal Therapeutics
|
Biotechnology | acquisition | — | Detail |
Sep 25, 2006
Schwarz Pharma AG
|
Medical | acquisition | € 4.40M | Detail |
Nov 22, 2011
Lectus Therapeutics
|
Biotechnology | acquisition | — | Detail |
Jun 6, 2017
Beryllium Discovery
|
Biotechnology | acquisition | — | Detail |